An FDA advisory panel has recommended that the agency approve Sanofi-Pasteur's (Lyon, France, www.sanofipasteur.com) H5N1 bird flu vaccine.
An FDA advisory panel has recommended that the agency approve Sanofi-Pasteur’s (Lyon, France, www.sanofipasteur.com) H5N1 bird flu vaccine. The panel voted 13–0 with one abstention. The vaccines and related biological products advisory committee agreed on February 27, 2007, that the data were sufficient to support the vaccine’s effectiveness during a pandemic.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.